EU Third-Party Medicines
EU Audiences
All product information provided is intended for European Union audiences only. These products may not be available in all Member States of the EU or in countries outside the EU; they may be available under a different trademark, in different strengths, or for different indications. Countries outside the EU may have different regulatory and labeling requirements that would call for different information to be available.
EU Medicines Using Alkermes' Technologies
We have granted licenses under our proprietary technologies to enable third parties to develop, commercialize and, in some cases, manufacture products for which we receive royalties and/or manufacturing revenues. Such arrangements with respect to products commercialized in the European Union include the following:
*RISPERDAL CONSTA®, TREVICTA® and XEPLION®, Janssen products, utilize Alkermes’ proprietary extended-release microsphere technology, proprietary technology and proprietary nanoparticle injectable extended-release technology, respectively.
FAMPYRA® is a registered trademark of Acorda Therapeutics, Inc. RISPERDAL CONSTA®, TREVICTA® and XEPLION® are registered trademarks of Johnson & Johnson or its affiliated companies.